Bluebird moves ahead with gene therapy despite NIH recommendation; China's biotech sector comes of age;

@FierceBiotech: ICYMI: Sanofi and Regeneron's would-be blockbuster clears FDA hurdle, but questions remain. Article | Follow @FierceBiotech

@JohnCFierce: Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA. News | Follow @JohnCFierce

@DamianFierce: This seems to be driving the PCSK9 panelists insane. Item | Follow @DamianFierce

> Bluebird bio ($BLUE) is pressing on with plans for a new pediatric study of its gene therapy for a rare blood disorder despite the recommendation of an NIH committee, which suggested the company wait a year or two before proceeding. More

> China's push to catch up with other nations in biotech R&D is bearing fruit, Reuters reports. Story

> Israel's Intec Pharma is looking to raise $46 million in a U.S. IPO to support its development of a novel drug delivery technology. Filing

Medical Device News

@FierceMedDev: ICYMI yesterday: HeartWare tells patients how to safely use its blood pump in attempt to overcome slew of recent recalls. Article | Follow @FierceMedDev

@VarunSaxena2: India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. FierceDrugDelivery article | Follow @VarunSaxena2

> Biotronik's vascular stent determined effective in challenging cases of peripheral artery disease. Story

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for almost $1.2B. Article

Pharma News

@FiercePharma: GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Does brand + generic really add up? Sandoz, Actavis execs count the ways. Article | Follow @CarlyHFierce

> Inflectra vs. Remicade study could be just what the doctor ordered for biosimilars. More

> Novartis closes in on lucrative new Cosentyx use with ankylosing spondylitis results. Story

> You're free to speak, FDA tells Amarin in bid to deflate free-speech suit. Article

Pharma Marketing News

> Merck KGaA's amped-up consumer pitch delivers much-needed sales hike. Story

> Pharma needs some 'marriage counseling' for patient relationships: report. More

> Merck's best hep C strategy is niche marketing, game theory expert figures. Story

> Want new patient relationships? Digital-savvy KOLs could be your intro. Article

> Why sue, FDA asks Amarin: You can spread the word on Vascepa already. Item

Biotech Research News

> CRISPR-Cas9 furor highlights explosive growth of gene editing in China. Report

> Do U.S. biomedical researchers really waste about $28B a year? Story

> Enzyme in mice linked to obesity, diabetes. Item

> NYU study: Blocking receptor protein CXCR4 'decimated' leukemia cells. More

> ALS researchers at Gladstone, Michigan shed new light on a key drug target. Article

Diagnostics News

> Study identifies 16 new genetic variants of Bloom syndrome. News

> U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. Report

> Health Diagnostic Laboratory rails against physician kickback claims. Story

> Roche receives FDA clearance for test to diagnose herpes using its cobas system. Article

> Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.